Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting

Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting
01 May 2013 pulse

Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting

San Diego, CA, USA – May 1, 2013 –

The following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego, CA:

Androgen deprivation therapy by a gonadotropin releasing hormone antagonist, degarelix, lowers the risk of cardiovascular events or death when compared to luteinising hormone-releasing agonists
(Abstract 781)

Date: Monday, May 6, 2013; 8:00-10:00 AM
Session/Type: Prostate Cancer: Advanced (II); Moderated Poster
Location: San Diego Convention Center, Room 7
Authors: Peter Albertsen; Bertrand Tombal; Thomas Wiegel; Egbert van der Meulen; Bo-Eric Persson; Tine Kold Olesen; Joshua Beckman

Analysis of disease control-related outcomes from six comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists
(Abstract 716)

Date: Sunday, May 5, 2013; 3:30-5:30 PM
Session/Type: Prostate Cancer: Advanced (I); Podium Presentation
Location: San Diego Convention Center, Room 1
Authors: Neal Shore; Kurt Miller; Bertrand Tombal; E. David Crawford; Cathrina Karup; Egbert van der Meulen; Bo-Eric Persson

Per AUA media embargo policy, coverage of research being presented is prohibited before the date and time of presentation.

About Ferring

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries.

To learn more about Ferring or its products, please visit www.ferring.com.

For more information, please contact

Molly Wilson
Tonic Life Communications
+1 (215) 928-2357
molly.wilson@toniclc.com

Patrick Gorman
Ferring Pharmaceuticals
+41 (0) 58 301 00 53
patrick.gorman@ferring.com

 

© 2013 Ferring B.V.
FIRMAGON® is a registered trademark of Ferring B.V.

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK